CPT code 0999T denotes the collection of a patient’s own immature muscle cells (muscle progenitor cells), an autologous tissue-harvesting procedure that may use ultrasound guidance. This emerging-service code is relevant as regenerative medicine and cell-based therapies expand across specialty care, creating new billing and coverage considerations nationally. Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical intent and setting for the code, an overview of payer coverage patterns where available, and contextual benchmarks and policy updates that affect billing and reimbursement for novel cell-collection services. The publication outlines service-line implications for specialty practices and ambulatory procedural centers, summarizes common documentation and coding considerations tied to autologous cell procurement, and highlights areas where payers commonly seek clinical rationale or prior authorization. Data not available in the input is identified explicitly; the focus remains on clarifying what CPT code 0999T represents, typical sites of service, and the administrative and payer-facing issues providers and billing staff are likely to encounter when submitting claims for autologous muscle progenitor cell collection.